Apple ( AAPL ) was in focus on Monday as investment firm Melius Research reiterated its Buy rating on the iPhone maker. “Given Apple’s free cash flow and we are about to embark on one of its most lucrative product rollouts since the big screen iPhones in 2014 - there is a case for Apple’s stock regaining some ground,” Melius analysts wrote in a note to clients. Apple shares were modestly higher in...
Apple ( AAPL ) was in focus on Monday as investment firm Melius Research reiterated its Buy rating on the iPhone maker. “Given Apple’s free cash flow and we are about to embark on one of its most lucrative product rollouts since the big screen iPhones in 2014 - there is a case for Apple’s stock regaining some ground,” Melius analysts wrote in a note to clients. Apple shares were modestly higher in premarket trading. Lately, Apple has announced the iPhone 17e and a refreshed iPad Air , a new MacBook Air, a MacBook Pro, new Studio Displays, the MacBook Neo , and an updated version of its over-the-ear headphones, the AirPods Max 2 . Apple shares were modestly higher in premarket trading but have lost some 8% year-to-date. Over the past 12 months, shares have gained 12%. More on Apple Apple's 50th Anniversary: A 'Solid Hold' For Wealth Preservation Apple Stock Price Firms Near $252 After WWDC Date Steadies Sentiment Apple Stock Price Slips At $252 As Tech Investors Pivot To Defensive Positioning Catalyst Watch: Jobs report, Nike earnings, and Apple turns 50 Apple hires ex-Google marketing exec for AI push
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Nicolae Popescu/iStock via Getty Images Since my article , "My Top 5 Biotech Stocks Big Pharma Could Buy Next," Kamada shares ( KMDA ) have risen 22.4%, outperforming the so-called "bellwether" for the biotech investors, the iShares Biotechnology ETF [6.5% return] ( IBB ), as well as the S&P 500 [-3.9%] ( SPY ). And to my surprise, this happened even after it announced on December 8 last year that...
Nicolae Popescu/iStock via Getty Images Since my article , "My Top 5 Biotech Stocks Big Pharma Could Buy Next," Kamada shares ( KMDA ) have risen 22.4%, outperforming the so-called "bellwether" for the biotech investors, the iShares Biotechnology ETF [6.5% return] ( IBB ), as well as the S&P 500 [-3.9%] ( SPY ). And to my surprise, this happened even after it announced on December 8 last year that it was discontinuing its Phase 3 InnovAATe study [ NCT04204252 ], because Inhaled AAT was unlikely to improve lung function measured by FEV1. On the other hand, KMDA's revenue rose 11.8% year-over-year to $44.12 million , beating my "base case" scenario by $1.6 million. And its non-GAAP EPS came below the consensus estimate, as it had in 2 of the previous 7 quarters, but this time by 2 cents . Source: graph was made by Author based on Seeking Alpha Now, I will start to answer whether, according to my "ALLKA 4D Rating" model, Kamada still has an appealing risk/reward ratio or whether it's time to downgrade its rating from Buy to Hold or even to Sell. Kamada is capturing the plasma market So, I will continue with Kamada's Proprietary Products segment, which is quite rich and includes 8 medications . Source: graph was made by Author based on the 20-F of Kamada Because it's one of the leaders in the plasma-derived medicinal products market, the revenue of this unit grew 21.7% year-on-year to $38.2 million in Q4. Source: graph was made by Author based on the financial reports of Kamada And to be more specific, in my view, the two key drugs are KamRAB/KedRAB and Glassia. The first one is HRIG, approved by the FDA , among other regulatory authorities, for transient post-exposure prophylaxis. By the way, KedRab's mechanism of action is quite simple. After injection at the site of the bite, neutralizing antibodies bind to the rabies virus and, as a result, prevent progressive encephalomyelitis . And according to PubMed, if this neurological condition is left untreated, it causes ov...
(RTTNews) - Velo3D Inc. (VELO), a metal 3D printing technology company, on Monday said it has been awarded a $9.8 million multi-year contract from the Department of War supporting the Defense Logistics Agency.
(RTTNews) - Velo3D Inc. (VELO), a metal 3D printing technology company, on Monday said it has been awarded a $9.8 million multi-year contract from the Department of War supporting the Defense Logistics Agency.
UBS AG is telling investors to seek protection against potential losses in emerging-market credit as the fallout from the escalating war in Iran threatens developing economies. The Swiss bank recommends positioning in an emerging-market index of credit-default swaps, known as the Markit CDX-EM index, alongside selective bearish bets in developing-nation currencies. While the conflict has roiled EM...
UBS AG is telling investors to seek protection against potential losses in emerging-market credit as the fallout from the escalating war in Iran threatens developing economies. The Swiss bank recommends positioning in an emerging-market index of credit-default swaps, known as the Markit CDX-EM index, alongside selective bearish bets in developing-nation currencies. While the conflict has roiled EM stocks and local yields as oil surged, credit spreads have shown a more muted reaction, leaving them vulnerable to further swings. “We see CDX-EM and selected shorts in EMFX as attractive hedges to further possible energy disruption in coming weeks,” strategists including Manik Narain wrote in a note on Monday. Last week, Morgan Stanley similarly advised hedging via the same CDS index, targeting a spread of 240 basis points with a stop at 180 basis points. The current spread is hovering around 197 basis points. “In the absence of a sustained de-escalation in the Middle East, we expect spreads to widen, reflecting increasingly persistent negative economic impacts,” strategists including Simon Waever wrote in a note dated March 23. Spreads have been little changed since the recommendation. The new CDS index composition is more skewed toward high-yield names following the addition of several junk-rated issuers, with such debt now accounting for 55% of the index, up from 47%, Waever wrote. Regionally, the bank expects Latin America to continue outperforming, citing attractive risk-reward opportunities in credits ranging from Ecuador to Argentina.
As the healthcare industry scrambles to integrate artificial intelligence, Eli Lilly is signaling it was already ahead of the curve. InSilico, a self-professed “AI-driven biotech company,” unveiled a deal with the drugmaker Sunday that could be valued at up to $2.75 billion. Under the terms of the arrangement, Lilly will receive exclusive worldwide rights to manufacture and sell oral treatments di...
As the healthcare industry scrambles to integrate artificial intelligence, Eli Lilly is signaling it was already ahead of the curve. InSilico, a self-professed “AI-driven biotech company,” unveiled a deal with the drugmaker Sunday that could be valued at up to $2.75 billion. Under the terms of the arrangement, Lilly will receive exclusive worldwide rights to manufacture and sell oral treatments discovered using InSilico’s Pharma.AI model.
Monty Rakusen/DigitalVision via Getty Images This is a classic case of a narrative outrunning the business. Amprius Technologies, Inc. ( AMPX ) is a ~$2.2B hardware company with ~11% gross margins, deeply negative operating margins, and a history of cash burn—yet it trades at ~30x trailing sales after a 10x move in under a year—a move that reflects not just improving fundamentals but significant n...
Monty Rakusen/DigitalVision via Getty Images This is a classic case of a narrative outrunning the business. Amprius Technologies, Inc. ( AMPX ) is a ~$2.2B hardware company with ~11% gross margins, deeply negative operating margins, and a history of cash burn—yet it trades at ~30x trailing sales after a 10x move in under a year—a move that reflects not just improving fundamentals but significant narrative expansion. Moves like this typically resolve with violent mean reversion, not stability. The stock is being valued like a differentiated, defensible winner in next-generation batteries—almost like a high-margin platform. It isn’t. This is a capital-intensive manufacturing business where mistakes show up in cash burn, not PowerPoint. Long-term outcomes are determined by cost curves, yield, and supply chain execution. Investors are not being paid for execution risk—they are underwriting perfection. That is how you lose money in hardware. The fundamentals don’t support the valuation. 2025 revenue was $73M (+200% YoY), with gross margins improving to 11.3%. Management is guiding to ~$125M in 2026 revenue alongside positive adjusted EBITDA of at least $4 million, but the business still depends heavily on third-party manufacturing and carries a $120M shelf registration. Even if guidance is met, the valuation leaves no room for delays, dilution, or margin pressure—standard operating reality in hardware, not downside scenarios. The manufacturing model is a key, underappreciated risk. Without full control of production at scale, it is harder to defend margins, resolve yield issues quickly, or drive unit cost reductions. That matters when competing against players with vastly greater capital and manufacturing leverage. The competitive landscape is far more serious than the market is pricing. Silicon-anode batteries are not a greenfield opportunity—they are a crowded, capital-rich battleground. Well-funded players like Sila Nanotechnologies and Group14 are scaling automotive-...
Royal Welsh College of Music and Drama, Cardiff Moving from Schubert through Chopin to Liszt, the young pianist brought deep interpretative insights Moving from Schubert through Chopin to Liszt, this recital by Alim Beisembayev – the Kazakh-born winner of 2021’s Leeds international piano competition – described an arc delineating the passionate surge of Romanticism over the span of 30 or so years ...
Royal Welsh College of Music and Drama, Cardiff Moving from Schubert through Chopin to Liszt, the young pianist brought deep interpretative insights Moving from Schubert through Chopin to Liszt, this recital by Alim Beisembayev – the Kazakh-born winner of 2021’s Leeds international piano competition – described an arc delineating the passionate surge of Romanticism over the span of 30 or so years from the 1820s to 1853. Beisembayev’s approach to Schubert’s Moments Musicaux, D780, was calm and understated, perhaps as a way of underlining the vast contrast with the Liszt yet to come. Using the fine acoustic of the Dora Stoutzker hall to his advantage, he created an intimacy where Schubert’s characteristic slipping in and out of major and minor modes was quietly evocative. Tellingly, the two Moments in F minor – No 3 where sadness and insouciance dance together and No 5 with its more dramatic outbursts – presaged the key of Chopin’s Fantaisie, Op49. Continue reading...
The VIX has climbed 41% in a single month, sitting at 26.95 and in the 93rd percentile of the past year’s readings. For retirement investors who felt last April’s volatility spike to 52.33, that environment raises a pointed question: is a smoother ride worth the cost of a slower one? iShares MSCI Global Min Vol ... The Low-Volatility Promise of ACWV Costs Investors 118% Over a Decade Compared to S...
The VIX has climbed 41% in a single month, sitting at 26.95 and in the 93rd percentile of the past year’s readings. For retirement investors who felt last April’s volatility spike to 52.33, that environment raises a pointed question: is a smoother ride worth the cost of a slower one? iShares MSCI Global Min Vol ... The Low-Volatility Promise of ACWV Costs Investors 118% Over a Decade Compared to SPY
RyanJLane/E+ via Getty Images Scary times, nowhere to hide In Q1 2026 a lot of things have been turned upside down. Unfortunately, not in a positive way. The unanimous consensus that the Wall Street analysts had for 2026 bringing new record high in the S&P 500 ( SPY ) has been increasingly replaced by a debate about potential recession. The interest rate path seems to be indicating an imminent u-t...
RyanJLane/E+ via Getty Images Scary times, nowhere to hide In Q1 2026 a lot of things have been turned upside down. Unfortunately, not in a positive way. The unanimous consensus that the Wall Street analysts had for 2026 bringing new record high in the S&P 500 ( SPY ) has been increasingly replaced by a debate about potential recession. The interest rate path seems to be indicating an imminent u-turn: i.e., cuts being priced out and replaced with higher and higher probabilities of hikes. Going into 2026 growth names such as Nvidia Corporation ( NVDA ), Amazon ( AMZN ) and Tesla ( TSLA ) already were under pressure as the capital was fleeing into value and high-quality areas of market. What has happened now is that the growth has remained on a declining trajectory with value ( VTV ) reversing the course and joining the party of negative repricing. The same applies to small-caps ( IWM ) and international equity ( SCHF ). The small-cap factor has lost its steam because of high-for-longer interest rate scenario. International equity has started to suffer because of stronger dollar and more tangible headwinds from soaring oil prices as most non US developed economies are net importers of oil and gas (or LNG). High duration or interest rate sensitive asset classes also have fallen under the chopping block. It is not only private credit ( BIZD ) and high-yield names ( PDI ) that have experienced unfavorable price dynamics (very logical given the risk-off mode). The pressures (mostly from elevated long-term interest rates) have spilled over to REITs ( VNQ ) and infrastructure ( BIP ) - irrespective of underlying asset quality. And, of course, anything that has to do with speculation and aggressive risk taking such as Bitcoin USD ( BTC-USD ), equity CLOs ( XFLT ), and silver ( SLV ) has massively sold-off. For prudent income investors (including retirees), who rely on portfolio cash flows (or are in the process of snowballing the necessary mass of income) the obvious issue n...
Rafael_Wiedenmeier/iStock Unreleased via Getty Images Amcor ( AMCR ) is a global leader in consumer packaging. Following its combination with Berry, it has fortified that position. The stock is trading at historically low multiples with a forward P/E ratio of 10x, and a juicy dividend yield of 6.5% , backed by a 69% payout ratio and a stable free cash flow stream. The integration of Berry is a lon...
Rafael_Wiedenmeier/iStock Unreleased via Getty Images Amcor ( AMCR ) is a global leader in consumer packaging. Following its combination with Berry, it has fortified that position. The stock is trading at historically low multiples with a forward P/E ratio of 10x, and a juicy dividend yield of 6.5% , backed by a 69% payout ratio and a stable free cash flow stream. The integration of Berry is a long and complex process that will take years to complete, but so far synergies have exceeded expectations. Also, the balance sheet is on a path to deleveraging, and the business is supported by a series of competitive advantages that do not constitute a wide moat but allow for a stable revenue base. All this leads me to conclude that the dividend is relatively safe. At current price levels, AMCR offers an attractive combination of high income through dividends and potential capital appreciation, making it a strong candidate for a defensive position in a diversified portfolio. I rate Amcor as a Buy. Global leader in packaging I have no idea what the AI world will look like, but I am certain that humans will still be buying packaged products. Millions of people around the globe come into contact with packaging produced by Amcor every single day. This is due to the global footprint of the company, which, following the $8.4 billion all-stock merger with Berry Global that closed in April 2025, operates 400+ locations in 40+ countries. Amcor generates around $23 billion in revenue , of which 51% comes from North America, 28% from Western Europe, and the remainder from emerging markets. The firm’s products are segmented into flexible packaging, representing 57% of revenue, and rigid packaging, the remaining 43%. For multinationals like Coca-Cola ( KO ), PepsiCo ( PEP ), or McDonald's ( MCD )—all of which are AMCR’s clients—working with smaller regional packaging manufacturers is not a viable option because they require high and consistent quality across all geographies. This underpi...